Navigation Links
3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration

- Companies to Focus Resources on Partnership to Develop Rapid Molecular

Tests for Healthcare-Associated Infections -

SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Gen-Probe (Nasdaq: GPRO) announced today that 3M has informed the Company it no longer intends to fund the companies' collaboration to develop rapid molecular assays for the food testing industry. The companies expect to formally terminate the collaboration in the coming days.

"Gen-Probe continues to believe that rapid molecular tests have the potential -- over time -- to increase the safety of the world's food supply," said Hank Nordhoff, Gen-Probe's chairman, president and chief executive officer. "In fact, the early technological successes we have achieved reinforce this belief. Nonetheless, our collaboration relies on 3M to assess the commercial readiness of the food testing market and to provide funding for our development efforts. Since 3M has decided not to continue funding our food testing collaboration, we plan to redeploy these resources to other high-value projects, including our separate partnership with 3M to develop rapid molecular tests for healthcare-associated infections."

Despite the expected termination of the food agreement, Gen-Probe anticipates recording milestone revenue of $2 million in the fourth quarter of 2007 associated with achieving technological feasibility for potential food testing assays. This revenue potential was contemplated in the financial guidance the Company provided on October 30. In 2008, the Company expects collaborative research revenues to be approximately $2 million less than previously anticipated due to the absence of development reimbursement from 3M related to the food testing collaboration.

"Food safety remains an important growth platform for 3M," said Chuck Kummeth, vice president and general manager, 3M Medical Division. "But we have chosen to focus on opportunities other than molecular food testing that are more economically attractive. This decision does not affect our separate partnership with Gen-Probe to develop nucleic acid tests to detect dangerous healthcare-associated infections such as methicillin-resistant Staphylococcus aureus (MRSA)."

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 24 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions, future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning management's objectives and future growth are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to: (i) the risk that molecular testing methods will not penetrate the food testing market, (ii) the risk that development efforts for MRSA or other projects may not be timely or successful, (iii) the possibility that new products will not be competitive or gain market acceptance, and (iv) the risk that collaborations cannot be maintained. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our Report on Form 10-K for the fiscal year ended December 31, 2006 and all our periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


Michael Watts

Sr. director, investor relations and corporate communications


SOURCE Gen-Probe Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. A new molecular zip code, and a new drug target for Huntingtons disease
2. New knock-out gene model provides molecular clues to breast cancer
3. Molecular probe paints cancer cells in living animals, Stanford researchers find
4. Story ideas from molecular & cellular proteomics
5. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
8. Molecular profiling can accurately predict survival in colon cancer patients
9. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
10. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
11. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Post Your Comments:
(Date:11/29/2015)... , ... November 29, 2015 , ... Effective immediately, every ... In addition starting on Black Friday Target is offering a “Buy One Scrub Set, ... is a rare opportunity to purchase IguanaMed at a discounted price. , ...
(Date:11/28/2015)... ... 2015 , ... Safe storage for contraceptive devices may not always be easy ... Jersey and the other from Bradley Beach, New Jersey, there is an easy solution ... having to replace NuvaRings more often than necessary. As such, it affords peace of ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back ... to choose from, the possibilities are endless. Users have full control over angle of ... Pulse masking effects, users are sure to get heads to turn. , ProPanel: Pulse ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... DUBLIN , Nov. 26, 2015 /PRNewswire/ ... announced the addition of the "2016 ... by Test, Country Volume and Sales Segment ... Emerging Opportunities" report to their offering. ... the addition of the "2016 Global ...
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... --> --> Juntendo University ... contrast weighting of MRI for patients with Multiple Sclerosis ... agreement with SyntheticMR in order to use SyMRI in clinical ... to generate multiple contrast images from a single scan and ... making it possible to both fine tune images and recreate ...
Breaking Medicine Technology: